Press Release

On September 1, 2022, LEGALBAND, a renowned legal directory, announced its "2022 Special Issue: China Top 15 Lawyers – Healthcare & Pharmaceuticals". The ranking identifies highly recommended lawyers in healthcare and pharmaceutical practice in mainland China. Aaron Gu, one of Han Kun's healthcare and pharmaceutical experts, was named in the list.

Reasons for selection: Prior to joining Han Kun, Mr. Gu practiced law with a well-known international law firm for many years. He has accumulated extensive service experience for corporate, regulatory compliance and licensing transaction projects in the life sciences, biopharmaceutical, medical, and healthcare industries. Mr. Gu's clients comprise bio-medicine and medical device companies and institutional investors spanning a wide range of industries and divisions. Mr. Gu is highly trusted by his corporate clients, owing to his high-quality legal services as well the analysis and proposal memos that he proactively prepares for clients on draft rules released by the NMPA and other Chinese governmental authorities. Mr. Gu is also active in attending media interviews and as a guest speaker in specialized events and seminars, where he continuously deepens his knowledge and understanding of the healthcare and pharmaceuticals field through discussions and by sharing views, aiming to enhance his professional services to clients. "Mr. Gu is able to provide expert-level legal services to meet clients' needs in a timely and efficient manner, which also exemplifies his unswerving commitment as a responsible, prudent and consummate legal practitioner."

Profile: Mr. Gu focuses on corporate, regulatory compliance and transactional services for the life sciences, biopharmaceutical, medical, and healthcare industries, including biosecurity and human genetic resource issues, clinical trial matters, product marketing authorizations, GxP compliance, drug licensing and collaboration, as well as regulatory issues involved in venture capital and private equity investments, mergers and acquisitions, and foreign and outbound investments in the life sciences industries. Mr. Gu also provides advocacy advice on draft laws and regulations released by the NMPA and other Chinese governmental authorities. Specifically, Mr. Gu's practice covers a full range of products including drugs (biologics and chemical drugs), medical devices, IVDs, cosmetics, general foods, special foods (health foods, foods for special medical purposes, and infant formulas), animal drugs, animal foods, etc. Mr. Gu has co-authored the China chapter of Editions 7, 8, 9, and 10 (2019-2022) of "The Life Sciences Law Review", Edition 6 (2022) of the Healthcare Law Review, and Chambers Life Sciences Global Practice Guide (2022). He has also been interviewed multiple times by media such as Het Financieele Dagblad (The Financial Daily, The Netherlands’ major medium) and International Pharmaceutical News for China.